Nanozymes: A novel approach to upgrade atherosclerosis treatment

Basit Öğe Kaydı
dc.authorid0000-0003-0312-9910
dc.authorid0000-0003-4056-1673
dc.contributor.authorMahjoubin-Tehran, Maryam
dc.contributor.authorKesharwani, Prashant
dc.contributor.authorAlamahmeed, Wael
dc.contributor.authorKarav, Sercan
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2026-02-03T12:02:39Z
dc.date.available2026-02-03T12:02:39Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAtherosclerosis has become a global health concern, contributing to the rise in cardiovascular diseases and causing significant morbidity and disability. The development of atherosclerosis begins with the accumulation of low-density lipoprotein (LDL) in the subendothelial space. As LDL becomes trapped in the arterial walls, reactive oxygen species (ROS) are generated, resulting in oxidative stress, impaired endothelial function, and oxidative modification of the retained LDL, forming oxidized LDL (ox-LDL). The oxidation of LDL to form ox-LDL is considered one of the most important factors in the development of atherosclerosis. Recently, there has been a growing interest in nanomaterials with enzyme-like characteristics called nanozymes in the field of biomedicine. The use of nanozymes has become increasingly popular because they offer solutions to the limitations associated with natural enzymes, including high costs, low stability, and challenging storage requirements. Nanozymes with anti-oxidative activities, such as catalase-, SOD-, and GPx-like nanozymes, have been extensively studied for various disease therapies, including atherosclerosis. Furthermore, nanozymes can be designed to have multiple enzyme-like activities. In this review, we aim to summarize studies that have used nanozymes as a therapeutic approach for the treatment of atherosclerosis. The results of this study have shown that nanozymes have a significant impact in reducing atherosclerotic plaques in ApoE- /- mice. This effect is mainly achieved through ROS scavenging, which leads to the suppression of foam cell formation and inflammation.
dc.identifier.doi10.1016/j.prp.2025.156005
dc.identifier.issn0344-0338
dc.identifier.issn1618-0631
dc.identifier.pmid40367896
dc.identifier.scopus2-s2.0-105008565452
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://doi.org/10.1016/j.prp.2025.156005
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34803
dc.identifier.volume271
dc.identifier.wosWOS:001492280700005
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Gmbh
dc.relation.ispartofPathology Research and Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectAtherosclerosis
dc.subjectNanozymes
dc.subjectReactive oxygen species
dc.subjectLow-density lipoprotein
dc.subjectNanotechnology
dc.titleNanozymes: A novel approach to upgrade atherosclerosis treatment
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu